Open AccessEligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011–2016
Author(s) -
Clarisse A. Tsang,
Neha Shah,
Lori Armstrong,
Suzanne Marks
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz263
Subject(s) - medicine , regimen , pyrazinamide , ethambutol , tuberculosis , population , pediatrics , mycobacterium tuberculosis , environmental health , pathology
In 2016, the World Health Organization (WHO) recommended a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to the conventional 18-24 month regimen) for patients without extrapulmonary TB, pregnancy, a previous second-line TB medication exposure, or drug resistance to pyrazinamide, ethambutol, kanamycin, moxifloxacin, ethionamide, or clofazimine. The recommendation was based on successful clinical trials conducted in Asia and Africa, but studies, using mainly European data, have shown few patients in higher-resource settings would meet WHO eligibility criteria.